Welcome to our dedicated page for ChronoScale SEC filings (Ticker: EKSO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ChronoScale's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ChronoScale's regulatory disclosures and financial reporting.
Ekso Bionics (EKSO) disclosed a Form 4 for CFO Jerome Wong. He sold 11,288 shares of common stock on November 10, 2025 at $4.799 per share to cover tax withholding upon the vesting and settlement of restricted stock awards.
After the transaction, Wong beneficially owns 26,009 shares directly and 2,876 shares indirectly via a 401(k). Share amounts reflect the issuer’s 1‑for‑15 reverse stock split effected on June 2, 2025.
Ekso Bionics (EKSO) reported an insider transaction by its Chief Operating Officer. On 11/10/2025, the executive sold 9,723 shares of common stock in a single transaction at $4.7990 per share. The filing states the sale was made to cover tax withholding obligations arising from the vesting and settlement of previously reported restricted stock awards.
Following the sale, the reporting person beneficially owns 27,211 shares directly and 3,141 shares indirectly through a 401(k). The company effected a 1‑for‑15 reverse stock split on June 2, 2025, and the reported amounts reflect that adjustment.
Ekso Bionics Holdings (EKSO) reported an insider transaction on Form 4. The reporting person, who serves as CEO and director, sold 23,315 shares of common stock on November 10, 2025 at $4.7990 per share. The filing states the sale was to cover tax withholding obligations arising from the vesting and settlement of restricted stock awards.
After the transaction, the reporting person beneficially owned 78,777 shares directly and 373 shares indirectly through a 401(k). The company previously effected a 1-for-15 reverse stock split on June 2, 2025, and the amounts in the filing reflect that adjustment.
Ekso Bionics Holdings (EKSO) disclosed an insider equity grant on Form 4. On 11/05/2025, the reporting person, a Director and CEO, received 80,000 restricted stock units (RSUs) at a price of $0, granted under the Amended and Restated 2014 Equity Incentive Plan. The award was fully vested at grant and settles in shares upon vesting. Following the transaction, the insider beneficially owned 102,092 shares directly and 373 shares via a 401(k). The company effected a 1-for-15 reverse stock split on 06/02/2025, and reported amounts reflect this adjustment.
Ekso Bionics Holdings (EKSO) reported an insider equity grant on Form 4. On November 5, 2025, the Chief Operating Officer received 15,000 restricted stock units (RSUs) at a stated price of $0. The filing states the award was fully vested at grant under the company’s Amended and Restated 2014 Equity Incentive Plan.
Following the transaction, the reporting person beneficially owns 36,934 shares directly and 3,141 shares indirectly via a 401(k). Share amounts reflect the 1-for-15 reverse stock split effected on June 2, 2025.
Ekso Bionics (EKSO) reported an insider equity award for its Chief Financial Officer. On 11/05/2025, the officer acquired 19,500 restricted stock units (RSUs) at $0 under the Amended and Restated 2014 Equity Incentive Plan. The filing states each RSU equals one share and the award was fully vested at grant.
Following the transaction, the officer beneficially owned 37,297 shares directly and 2,876 shares indirectly via a 401(k). The company previously implemented a 1-for-15 reverse stock split on June 2, 2025, and amounts reflect that adjustment.
Ekso Bionics Holdings approved new executive equity awards on November 5, 2025. Scott Davis, Jerome Wong, and Jason Jones received fully vested RSUs covering 80,000, 19,500, and 15,000 shares, respectively. Each also received cash‑settled Phantom PSUs covering 185,000, 40,000, and 32,000 notional shares that vest only if two conditions are met within five years: a Change in Control and a Stock Price of at least $7.50 as defined.
The company also entered into new Change in Control and Severance Agreements with each executive, replacing prior arrangements. If terminated outside a Change in Control, base salary continues for 6 months (or 9 months for Mr. Davis). If terminated within the Change in Control period (or upon Good Reason), severance includes a lump sum of 9 months base salary (or 18 months for Mr. Davis), COBRA premiums for the same periods, and full acceleration of time‑based equity awards. Payments require a release and include a 280G best‑net cutback provision.
Ekso Bionics Holdings, Inc. announced a registered direct offering of 769,490 shares of common stock at $4.81 per share. The company expects approximately $3.2 million in net proceeds after fees and expenses, with intended uses for general corporate purposes, including R&D, SG&A, strategic initiatives, and working capital. The transaction is expected to close on or about October 30, 2025, subject to customary closing conditions.
In connection with the offering, Ekso entered a placement agency agreement with Lake Street Capital Markets. The company will pay a cash fee equal to 6% of gross proceeds and issue a placement agent warrant to purchase up to 15,389 shares at an exercise price of $4.81 per share. The placement agent warrant was offered in reliance on Section 4(a)(2) and the shares issuable upon exercise have not been registered.
Ekso Bionics (EKSO) is offering 769,490 shares of common stock at $4.81 per share under a prospectus supplement filed pursuant to Rule 424(b)(5). The offering totals $3,701,246.90 in gross proceeds. The placement agent fee is 6.0% ($222,074.82), resulting in $3,479,172.08 in proceeds before expenses and an estimated ~$3.2 million in net proceeds. Shares are expected to be delivered on or about October 30, 2025.
The company intends to use the net proceeds for general corporate purposes, including R&D, SG&A, strategic initiatives, and working capital. Shares outstanding will be 3,392,723 after the offering, based on 2,623,233 shares outstanding as of October 24, 2025. The offering was arranged by Lake Street Capital Markets as sole placement agent, which will also receive a Placement Agent Warrant to purchase up to 15,389 shares at $4.81.
As context, the filing notes Form S-3 I.B.6 limitations, citing a public float of approximately $14.3 million as of October 28, 2025, and prior sales of $1,008,975 in the preceding 12 months. The dilution section estimates $1.33 per share immediate dilution to new investors at the offering price.
Ekso Bionics Holdings, Inc. terminated its at‑the‑market offering program under its prior prospectus. The company previously sold 275,245 shares of common stock under that program, and the termination does not otherwise impact the sales agreement with H.C. Wainwright & Co.
As of October 28, 2025, the company’s public float was approximately $14.3 million, based on 2,623,233 shares outstanding (2,555,564 held by non‑affiliates) and a $5.60 per share closing price on October 3, 2025. Under General Instruction I.B.6 of Form S‑3, the company sold $1,008,975 during the prior 12 months and is eligible to offer and sell up to approximately $3,761,411 of securities pursuant to that instruction. The common stock last traded at $4.92 on Nasdaq on October 27, 2025.